The incremental risk of coronary bypass surgery was analyzed in 718 patients undergoing mitral valve replacement between 1971 and 1983. Ninety-eight patients (14%) had significant coronary artery disease requiring coronary bypass surgery. In 70 of these patients, the originofthe mitral valvediseasewasnonischemic, whereas 28 patients had ischemic mitral regurgitation unsuitable for conservative valve surgery.
There were six operative deaths (9% ) and four perioperative myocardial infarctions (6%) after mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease. Operative mortality was related to low output cardiac failure before operation or perioperative myocardial infarction. Actuarial curves predict survival (± standard error) of 55 ± 7% at 5 years and 43 ± 8% at 10 years. Preoperative functional Concomitant coronary artery disease has been reported to be one of the most powerful determinants of early and late mortality after mitral valve replacement (I). This has led to the practice of combining coronary bypass surgery with mitral valve replacement. Operative mortality for combined mitral valve replacement and coronary bypass surgery ranges from 3.5 (2) to 18% (3), the great variability reflecting the different origins of the valvular lesion (4, 5) .
There is little information on late survival after combined mitral valve replacement and coronary bypass surgery. We present a 10 year follow-up study of patients who underwent combined mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease. The survival data are compared with those of patients who underwent mitral valve replacement alone (6) and those who had combined mitral valve replacement and coronary bypass surgery for ischemic mitral valve disease (7) . The actuarial survival of the 620 patients without coronary artery disease who underwent mitral valve replacement alone was 63 ± 3% at 10 years. This was significantly better than that of the 70 patients who underwent mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease (p < 0.001). Conversely, 5 year survival of the 28 patients with ischemic mitral regurgitation was 43 ± 10%. This confirms the negative detrimental effect of an ischemic origin of mitral valve disease on survival after mitral valve replacement and coronary bypass surgery (p < 0.0001). 
Methods
Patients. Between 1971 and 1983, mitral valve replacement was performed in 718 patients. All patients underwent cardiac catheterization before operation. Coronary arteriography was performed in those older than 40 years of age.
Six hundred twenty patients without coronary artery disease underwent mitral valve replacement alone. The mean age of these patients was 52 years (range 28 to 82) and the male to female ratio was I: 2. Ninety-eight patients (14%) had significant coronary artery disease (defined as > 50% reduction in luminal diameter in at least one plane on biplane cinearteriography) requiring coronary bypass surgery. The origin of the mitral valve disease was rheumatic in 57 patients. degenerative in 13 patients and ischemic in 28 patients. The patients who underwent combined mitral valve replacement and coronary bypass surgery are analyzed in detail and grouped according to nonischemic and ischemic etiology.
Nonischemic mitral valve disease with associated coronary artery disease. The 70 patients in this group had primary mitral valve disease requiring valve replacement (Table I) . It has been our policy to perform coronary bypass MITRAL VALVE AND CORONARY BYPASS SURGERY surgery on all suitable patients with additional significant coronary artery disease. The mean age of the patients was 56 years (range 42 to 77), and 33 patients (47%) were male. The main presenting feature in all patients was dyspnea. Twenty-nine patients also complained of angina, seven of whom had had a previous myocardial infarction. Twentyeight patients (40%) had a localized wall motion abnormality on the left ventriculogram. Sixty-three patients (90%) received a ball and cage prosthesis. Forty-one patients (59%) received a single bypass graft, 17 (24%) received two grafts and 12 (17%) received three grafts (Table 2 ). Before 1978, the operation was performed using intermittent ischemic arrest at moderate hypothermia. Thereafter, cold cardioplegic arrest was used for myocardial protection in 13 patients.
Ischemic mitral valve disease. It has been our policy to treat patients with mild or moderate ischemic mitral regurgitation by coronary bypass surgery alone and, when this was insufficient, to attempt to repair the valve (7). The 28 patients who underwent mitral valve replacement and coronary bypass surgery in this group had severe ischemic mitral regurgitation and valve disease unsuitable for valve repair.
The mean age was 63 years (range 41 to 80) and 20 patients were male (71%) ( Table I) . Twenty-four patients (86%) were in New York Heart Association functional class IV. All patients had had a previous myocardial infarction, 20 (71%) of which occurred within I month of surgery. Eleven patients had a ruptured papillary muscle. six of whom have been previously described in detail (8) . Ten patients were in cardiogenic shock.
Twenty-five patients (89%) received a ball and cage prosthesis. Twelve patients (43%) received two coronary artery bypass grafts and 16 patients (57%) received three grafts ( Table 2) .
Perioperative myocardial infarction. The possibility of a perioperative myocardial infarction was evaluated in all patients, diagnosis being made on the basis of the following variables: I) new Q waves on the electrocardiogram, greater than 0.04 second in duration and greater than 3 mm in depth; 2) creatine kinase greater than 500 IV. with 10% specific (MB) myocardial isoenzyme; and 3) autopsy evidence of recent infarction.
Follow-up. All patients were followed up on a prospective basis using a combination of questionnaires and telephone contacts with both patients and referring physicians. The current status of the patients, determined in October 1983, was 96% complete. The mean length of followup (± standard deviation) was 6.2 ± 2 years for the group with mitral valve replacement only, 3.5 ± 2 years for the group with nonischemic mitral valve disease undergoing both valve replacement and coronary bypass surgery and 3.5 ± 3 years for the group with ischemic mitral valve disease undergoing both valve replacement and coronary bypass surgery.
Statistical analysis. The data were analyzed in an HP/3000 computer (Hewlett Packard) using the Statistical Package for Social Sciences (9) . The actuarial method ( 10) was used to calculate 5 and 10 year survival (± standard error). Survival curves were compared by an approximate chi-square method (9). 
Results
Operative mortality. The operative mortality in the 620 control patients who underwent mitral valve replacement alone was 6%. There were six (9%) operative deaths in the 70 patients who had mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease. Two of these patients had preoperative low output cardiac failure secondary to severe rheumatic mitral regurgitation, with incidental coronary artery disease. Three patients died after perioperative myocardial infarction. The sixth death occurred in a 64 year old patient who bled profusely from acute gastric erosions during the procedure and could not In the patients with nonischemic mitral valve disease, the 5 year survival rate for patients who underwent mitral valve replacement and coronary bypass surgery was 58 ± 8% for patients with mitral stenosis or mixed valvular lesions and also 58 ± 16% for the II patients with pure mitral be weaned from cardiopulmonary bypass. Four patients (6%) had a perioperative myocardial infarction; three of these infarctions occurred in the era before the introduction of cardioplegia and were fatal. Indeed, in the 13 patients protected by cold cardioplegic arrest, there were no deaths due to cardiac causes and a single, nonfatal perioperative myocardial infarction.
Four (14%) of the 28 patients who underwent mitral valve replacement and coronary bypass surgery for ischemic mitral valve disease died within I month of operation. The death was associated with acute preoperative myocardial infarction and cardiogenic shock in three patients and perioperative myocardial infarction in one patient.
Late mortality. The 10 year actuarial survival for the 620 patients who underwent mitral valve replacement alone was 63 ± 3%. There were 22 late deaths after mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease, corresponding to 3.6% per year. Four (18%) of these deaths were myocardial in origin and another four were prosthetic valve-related. Actuarial curves predicted a survival rate of 55 ± 7% at 5 years and 43 ± 8% at 10 years. This was significantly worse than that of the control group undergoing mitral valve replacement alone (p < 0.001) (Fig. I) .
Of the 24 operative survivors after mitral valve replacement and coronary bypass surgery for ischemic mitral valve disease, 9 patients died within the first year. All of these deaths were myocardial in origin. The 5 year actuarial survival rate in this group was 43 ± 10% (Fig. 2) . Thus, the ischemic origin of the mitral valve disease has an important negative effect on survival after mitral valve replacement and coronary bypass surgery (p < 0.0001).
Factors affecting survival in patients with nonischernie mitral valve disease. In the 70 patients who underwent combined mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease, a univariate 
Discussion
Incidence of combined valvular and coronary artery disease. With the recent trend toward mitral valve replacement in a more elderly population (I), the incidence of coronary artery disease has increased in these patients. In our series, 70 (10%) of 690 patients with nonischemic mitral valve disease had concomitant coronary artery disease requiring coronary bypass surgery. This is considerably lower than the 43% reported by Miller et al. (5) . However, in their series, which also included patients with ischemic mitral regurgitation, only 50% of the patients underwent coronary arteriography. The 10% incidence rate of coronary artery disease in our patients who had mitral valve replacement is considerably less than that of 27% for patients undergoing aortic valve replacement at the Oregon Health Sciences University (II). This is partly an age-related phenomenon, the mean age of patients who underwent combined mitral valve replacement and coronary bypass surgery being 56 years compared with 64 years for those who had the combined aortic procedure, and partly a sex-related phenomenon, 74% of the aortic group with valve replacement being male compared with 47% for the group with mitral valve replacement.
Fifty-nine patients (83%) with non ischemic mitral valve disease had predominant mitral stenosis. In many cases, the resulting small left ventricle had an adequate blood supply despite an impaired coronary circulation. Indeed, only 29 (41%) of these patients with concomitant coronary artery disease presented with angina. This lack of correlation between angina and coronary artery disease contradicts the conclusion of Bonchek et al. (12) that "coronary arteriography may be safely omitted before valve replacement in many patients with no symptoms of ischemic heart disease and no risk factors known to increase its significance". It strengthens our policy of performing coronary arteriography in all patients undergoing valve replacement (13) .
Operative mortality. Historically, combined mitral valve replacement and coronary bypass surgery has been associated with a high mortality rate (3). Karp (4) suggested that the rate is high because combined mitral valve and coronary artery disease produce a cardiomyopathy that is not reversible by valve replacement and coronary bypass surgery. In our series, the operative mortality rate was 9%. This is toward the lower end of the 3.5 to 18% range quoted by others (2) (3) (4) (5) . One of the main determinants of operative mortality in our patients who underwent mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease was perioperative myocardial infarction. This occurred in 6% of our patients, which is similar to the incidence reported by other surgical groups (5, 14) and is seemingly related to techniques of myocardial protection.
In those patients who underwent cold cardioplegic arrest, there were no early cardiac deaths and a single, nonfatal, perioperative myocardial infarction. Given the small numbers of patients involved, these data do not reach statistical significance, but it is our belief that cold cardioplegic arrest is the preferred method of myocardial protection for patients undergoing combined valve replacement and coronary bypass surgery. Reed et al. (2) , using cardioplegia in a more recent time frame (1978 to 1981), were able to report a 3.5% operative mortality rate for 28 patients who underwent combined mitral valve replacement and coronary bypass surgery.
Late survival. There is little information on late survival after the combined procedure. Miller et al. (5) reported a 53% 3 year survival for a mixed group of patients, including those with ischemic and non ischemic valve disease. They suggested that neither the presence of coronary artery disease nor the etiology of the valve lesion was important. Our results, however, suggest that coronary artery disease is an important variable in the survival of patients undergoing mitral valve replacement for rheumatic and degenerative mitral valve disease.
The patients undergoing mitral valve replacement for ischemic mitral regurgitation were a select group of patients whose valve was unsuitable for repair. They were older and had more severe coronary artery disease and left ventricular wall motion abnormalities than the patients undergoing mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease (Tables I and 2 ). Our conservative approach for ischemic mitral regurgitation is similar to that recommended by Kay et al. (15) , who reported a 33% 2 year survival rate for patients with ischemic mitral regurgitation requiring combined mitral valve replacement and coronary bypass surgery. In our series, the 5 year survival rate of patients who had the combined procedures for ischemic mitral valve disease was 43%. Thus, there was a significant difference in survival between patients who underwent mitral valve replacement and coronary bypass surgery for ischemic and nonischemic mitral valve disease.
Factors affecting survival in patients with nonischernie mitral valve disease. Preoperative functional class was an important predictor of long-term survival in those patients who underwent combined mitral valve replacement and coronary bypass surgery for nonischernic mitral valve disease. This did not appear to correlate with hemodynamic variables. Thus, we were unable to correlate pulmonary artery pressures or left ventricular end-diastolic pressure with operative mortality or long-term survival. This was partly due to the small number of patients involved and to the fact that the patients with an operative or late death could be divided into two groups representing extreme forms of a spectrum of disease: those with severe valve disease and incidental coronary artery disease and those with moderate valve disease and severe coronary artery disease. The latter combination proved deleterious since left ventricular damage in the form of previous myocardial infarction and segmental wall motion abnormality appeared to have a negative effect on 10 year survival. As the presence of coronary artery disease appeared to exert a significant effect on survival after mitral valve replacement, it might have been expected that the number of diseased coronary arteries would also have had an effect. This did not prove to be the case, which is in line with the long-term results of combined aortic valve replacement and coronary bypass surgery (11,16).
The negative effect of concomitant coronary artery disease requiring coronary bypass surgery on long-term survival after mitral valve replacement suggests either the presence of some permanent myocardial damage before operation, or its relentless advance, which was not reversed by myocardial revascularization. In the present climate of medical opinion, particularly with the success of coronary bypass surgery, it is unlikely that the question of whether diseased coronary arteries should be bypassed at the time of valve replacement will ever be answered formally by a prospective trial. Bonow et al. (17) attempted to justify the use of valve replacement alone in patients with both aortic valve disease and coronary artery disease, but were heavily criticized by Kirklin and Kouchoukos (18) for the small number of patients involved and the omission from the premise of patients with left main stem disease, Conclusions. I) Concomitant coronary artery disease requiring coronary bypass surgery is an important variable in the long-term survival of patients undergoing mitral valve replacement of nonischemic mitral valve disease. 2) Patients with ischemic mitral regurgitation unsuitable for treatment by valve-conserving measures who require mitral valve replacement have a diminished chance of survival compared with patients undergoing combined mitral valve replacement and coronary bypass surgery for nonischemic mitral valve disease.
